Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Expert Panel Member Sakamaki Wants Pricing Overhaul to Push Generic Industry Consolidation
February 6, 2023
-
BUSINESS Astellas EVP Okamura to Become CEO in April
February 6, 2023
-
BUSINESS Mitsubishi Chemical Calls It Quit for Medicago, COVID Jab
February 6, 2023
-
BUSINESS Chugai’s Sales Hit 1-Trillion-Yen Mark in 2022 on New Launches, Ronapreve
February 3, 2023
-
REGULATORY Chuikyo OKs Use of Multiple Comparators to Price Xocova, Upping of Reduction Cap Mooted for Re-Pricing
February 2, 2023
-
BUSINESS Daiichi Sankyo Taps CFO Okuzawa as New President, Set to Continue ADC Drive
February 1, 2023
-
BUSINESS Shionogi Logs Record Profits as Xocova Nets 100 Billion Yen from Govt Purchase: April-December
January 31, 2023
-
BUSINESS Lecanemab Earns Priority Review in Japan, Eisai Aims for Approval by Year-End
January 31, 2023
-
REGULATORY Panel OKs Japan’s First Abortion Pill, but Upper Organ to Review It Again after Public Comments
January 30, 2023
-
REGULATORY It’s Official: Japan to Downgrade COVID-19 Severity Status on May 8
January 30, 2023
-
REGULATORY Experts Doubt Necessity of Policy Intervention for LLP-Dependent Companies
January 27, 2023
-
REGULATORY Japan to Lower COVID-19 Severity Status on May 8
January 27, 2023
-
REGULATORY Chuikyo Begins Xocova Price Debate under Mega Seller Rule, Weighs Quicker Re-Pricing
January 26, 2023
-
ORGANIZATION PhRMA Poised to Issue 2024 Reform Proposal in Next Few Months: New Japan Chief
January 25, 2023
-
REGULATORY Xocova Might Trigger Mega Seller Price Control Rule for First Time
January 24, 2023
-
REGULATORY Setting “Presumed Efficacy” Criteria Would Be Difficult; Xocova Decision Reasonable: PMDA Chief
January 23, 2023
-
REGULATORY Japan to Downgrade COVID-19 Status to Seasonal Flu Level This Spring
January 23, 2023
-
BUSINESS Opdivo Outdistances Keytruda in 2022 with Sales Up 30 Billion Yen YOY: Encise
January 20, 2023
-
REGULATORY Former Minister Nemoto to Initiate Debates on Pharma Policies by Young Lawmakers
January 19, 2023
-
BUSINESS Ex-Sandoz Japan Chief Tapped to Spearhead Nichi-Iko Turnaround
January 18, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…